18F-mFBG PET Imaging in the Evaluation of Pheochromocytoma

Launched by FIRST AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY · Feb 6, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a special imaging test called 18F-metafluorobenzylguanidine (18F-MFBG) positron emission tomography (PET) to see how well it can help doctors evaluate and measure pheochromocytoma, a type of tumor that affects the adrenal glands. The goal is to find out how effective this imaging method is in diagnosing the condition and understanding the extent of the tumors.

To participate in this study, you need to be between 30 and 80 years old and have a confirmed diagnosis of pheochromocytoma. It's important that you have a caregiver who can help you and that you can understand the study requirements. However, if you have serious health issues or uncontrolled high blood pressure, or if you are pregnant or breastfeeding, you may not be eligible. If you join the trial, you can expect to undergo the PET imaging procedure, which is a non-invasive way to see what's happening inside your body. The researchers are looking for volunteers who can provide informed consent and follow the study's guidelines.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1) Aged 30-80 years old, primary school or above, with a regular caregiver; 2) Clinically diagnosed patients with pheochromocytoma; 3) Can provide informed consent, can understand and comply with the study requirements.
• Exclusion Criteria:
• • 1) Patients with serious primary diseases such as heart, brain, liver, kidney and hematopoietic system; 2) Uncontrolled hypertension or high-risk BP (i.e., systolic BP \> 180 mmHg or diastolic BP \> 110 mmHg); 3) Patients with mental disorders or primary affective disorders; 4) Unable to understand and adhere to the study protocol or provide informed consent; 5) Contraindications to PET imaging (including pregnant women, lactating women, and women of childbearing age with recent childbearing plans, etc.); 6) Allergy to imaging agents; 7) Patients who were unable to cooperate with PET scanning, such as hypoglycemia, severe pain or tremor.